Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2021 | 1 |
2022 | 1 |
2025 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Cancer Immunol Immunother. 2022 Jun;71(6):1531-1543. doi: 10.1007/s00262-021-03075-3. Epub 2021 Oct 18.
Cancer Immunol Immunother. 2022.
PMID: 34661709
Free PMC article.
Clinical Trial.
CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotype.
Dharmadhikari B, Nickles E, Harfuddin Z, Ishak NDB, Zeng Q, Bertoletti A, Schwarz H.
Dharmadhikari B, et al.
Cancer Immunol Immunother. 2018 Jun;67(6):893-905. doi: 10.1007/s00262-018-2144-x. Epub 2018 Mar 5.
Cancer Immunol Immunother. 2018.
PMID: 29508025
Free PMC article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.